We sat down with oncologist Lennard Lee to discuss why he hopes these vaccines will prove to be the “silver lining of the pandemic.”
🎯#TNBC patient case CME w/ @dr-rshatsky.bsky.social y.social & @ptarantinomd.bsky.social
✍️Supported by an edu grant from Gilead Sciences
🆓 #CME info 🔗 bit.ly/tnbc_casesim
Provided by @bonumce.bsky.social
🖱️👇Scroll down to start
🎯#TNBC patient case CME w/ @dr-rshatsky.bsky.social y.social & @ptarantinomd.bsky.social
✍️Supported by an edu grant from Gilead Sciences
🆓 #CME info 🔗 bit.ly/tnbc_casesim
Provided by @bonumce.bsky.social
🖱️👇Scroll down to start
They were fired to give more money to billionaires.
#DOGEkills
#medsky
www.propublica.org/article/trum...
They were fired to give more money to billionaires.
#DOGEkills
#medsky
www.propublica.org/article/trum...
"It’s not just about vaccines or pandemics – misinformation about ADHD, cancer treatments, weight loss, fertility & chronic disease management thrives online."
"It’s not just about vaccines or pandemics – misinformation about ADHD, cancer treatments, weight loss, fertility & chronic disease management thrives online."
#MedSky
We have job openings nationwide. www.canada.ca/en/immigrati...
#MedSky
#MedSky
#MedSky
👉For instance: Feb 2024, ARV-471, an investigational, oral PROTAC studied in the phase 3 VERITAC-2 trial, received FDA fast-track designation.
www.pfizer.com/news/announc...
👉For instance: Feb 2024, ARV-471, an investigational, oral PROTAC studied in the phase 3 VERITAC-2 trial, received FDA fast-track designation.
www.pfizer.com/news/announc...
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i